2024 JP Morgan Healthcare Conference
BRUKER'S TRANSFORMATION INTO A FAST GROWTH COMPANY
■
Dual strategy of Project Accelerate 2.0 and Operational Excellence works
Project Accelerate 2.0 Initiatives
▪ Pull up growth and EPS
Re-positioning Bruker for high-growth, high- Assays, Software
margin opportunities
& Aftermarket
Building unique, leading platforms for
novel applications, life-science solutions
Enabling research in cell and disease
biology: large TAMS, strong secular growth
▪ Project Accelerate 2.0 at ~56% of revenue,
with DD revenue CAGR
→ Major benefits from Al and Clean-Tech
→ Leadership in the Post-Genomic Era
© 2023 Bruker
Next-gen Nano
& Semi Tools
Unbiased
Proteomics &
Multiomics
BRUKER
Biopharma &
Applied
Microbiology &
Molecular Dx
Spatial Biology,
Single-Cell Omics,
Cellular Analysis
Operational Excellence
▪ Push up market share, gross margin
▪ Bruker Management Process drives
execution and predictability
■
BRUKER
■
Operational, commercial and
product R&D excellence
Disciplined execution: significant
R&D investments, while delivering
organic margin expansion and non-
GAAP EPS growth - all at high ROIC
Prudent capital allocation with
conservative margin of safety
Innovation with Integrity | January 8, 2024
I
3View entire presentation